International Hepatology

A recent study by Prof. Wai-Kay Seto (The University of Hong Kong) and Prof. Jie Li (Drum Tower Hospital, Nanjing University Medical School), published in Alimentary Pharmacology & Therapeutics, systematically reviewed the epidemiology, pathogenic mechanisms, and prognostic impact of alcohol use in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), showing that alcohol consumption significantly complicates disease progression and prognosis.

Guangzhou, China, July 26, 2025 — In a significant move to advance global efforts in the fight against hepatocellular carcinoma (HCC), the Chinese Anti-Cancer Association Liver Cancer Committee (CACA-LCC) and…

At a recent international roundtable, experts from China, Germany, and Japan shared their perspectives on the TALENT study, which evaluated the combination of TACE with atezolizumab and bevacizumab for…

Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially in patients with risk factors like large tumor size,…

Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases” and participated in an in-depth interview with International Hepatology. In his address, Academician Dong presented IDEAL—China’s first multimodal intelligent system for precision surgical decision-making in liver diseases. He explained how IDEAL enhances the accuracy, safety, and minimally invasive nature of liver surgery, offering patients greater health benefits. Dong also emphasized the transformative role of digital technologies in surgical care, predicting their impact across clinical evaluation, surgical planning, decision-making, and data management, thus accelerating innovation in the field of hepatobiliary surgery.

In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…

In a recent editorial published in the Journal of Hepatology (March 24, 2025), Professors Debbie Shawcross and Vishal C. Patel spotlight the THEMATIC trial—a phase II RCT investigating the safety…

Highlights of the Congress The 34th Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL) concluded successfully in Beijing on March 30, 2025. Under the theme…

We’re honored to present an exclusive dialogue featuring Professor Julien Calderaro, President of the 2025 EASL Liver Cancer Summit, and Professor Jian Zhou from Zhongshan Hospital, Fudan University and the President of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE).

Liver diseases remain a global challenge with complex diagnostic and therapeutic hurdles. Addressing these requires not only pooling the expertise of global specialists but also integrating valuable experiences from both Eastern and Western medical practices.